Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04745832
Title Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors MEI Pharma, Inc.
Indications

follicular lymphoma

marginal zone B-cell lymphoma

Therapies

Rituximab + zandelisib

Bendamustine + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN | BEL


No variant requirements are available.